222 related articles for article (PubMed ID: 23859777)
41. Novobiocin-ferrocene conjugates possessing anticancer and antiplasmodial activity independent of HSP90 inhibition.
Mbaba M; de la Mare JA; Sterrenberg JN; Kajewole D; Maharaj S; Edkins AL; Isaacs M; Hoppe HC; Khanye SD
J Biol Inorg Chem; 2019 Mar; 24(2):139-149. PubMed ID: 30542925
[TBL] [Abstract][Full Text] [Related]
42. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
43. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
[TBL] [Abstract][Full Text] [Related]
44. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.
Marcu MG; Chadli A; Bouhouche I; Catelli M; Neckers LM
J Biol Chem; 2000 Nov; 275(47):37181-6. PubMed ID: 10945979
[TBL] [Abstract][Full Text] [Related]
45. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity.
Donnelly AC; Mays JR; Burlison JA; Nelson JT; Vielhauer G; Holzbeierlein J; Blagg BS
J Org Chem; 2008 Nov; 73(22):8901-20. PubMed ID: 18939877
[TBL] [Abstract][Full Text] [Related]
46. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer.
Forsberg LK; Liu W; Holzbeierlein J; Blagg BSJ
Bioorg Med Chem Lett; 2017 Sep; 27(18):4514-4519. PubMed ID: 28844386
[TBL] [Abstract][Full Text] [Related]
47. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors.
Zaarur N; Gabai VL; Porco JA; Calderwood S; Sherman MY
Cancer Res; 2006 Feb; 66(3):1783-91. PubMed ID: 16452239
[TBL] [Abstract][Full Text] [Related]
48. Exploiting polarity and chirality to probe the Hsp90 C-terminus.
Forsberg LK; Davis RE; Wimalasena VK; Blagg BSJ
Bioorg Med Chem; 2018 Jul; 26(12):3096-3110. PubMed ID: 29720349
[TBL] [Abstract][Full Text] [Related]
49. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.
Sadikot T; Swink M; Eskew JD; Brown D; Zhao H; Kusuma BR; Rajewski RA; Blagg BS; Matts RL; Holzbeierlein JM; Vielhauer GA
Assay Drug Dev Technol; 2013 Oct; 11(8):478-88. PubMed ID: 24127661
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
Kim HS; Hong M; Ann J; Yoon S; Nguyen CT; Lee SC; Lee HY; Suh YG; Seo JH; Choi H; Kim JY; Kim KW; Kim J; Kim YM; Park SJ; Park HJ; Lee J
Bioorg Med Chem; 2016 Nov; 24(22):6082-6093. PubMed ID: 27745993
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.
Taddei M; Ferrini S; Giannotti L; Corsi M; Manetti F; Giannini G; Vesci L; Milazzo FM; Alloatti D; Guglielmi MB; Castorina M; Cervoni ML; Barbarino M; Foderà R; Carollo V; Pisano C; Armaroli S; Cabri W
J Med Chem; 2014 Mar; 57(6):2258-74. PubMed ID: 24588105
[TBL] [Abstract][Full Text] [Related]
52. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.
Zhao H; Anyika M; Girgis A; Blagg BS
Bioorg Med Chem Lett; 2014 Aug; 24(15):3633-7. PubMed ID: 24953820
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.
Yao H; Xu F; Wang G; Xie S; Li W; Yao H; Ma C; Zhu Z; Xu J; Xu S
Eur J Med Chem; 2019 Apr; 167():485-498. PubMed ID: 30784881
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
[TBL] [Abstract][Full Text] [Related]
55. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
56. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
[TBL] [Abstract][Full Text] [Related]
57. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.
Shelton SN; Shawgo ME; Matthews SB; Lu Y; Donnelly AC; Szabla K; Tanol M; Vielhauer GA; Rajewski RA; Matts RL; Blagg BS; Robertson JD
Mol Pharmacol; 2009 Dec; 76(6):1314-22. PubMed ID: 19741006
[TBL] [Abstract][Full Text] [Related]
58. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives as novel heat shock protein 90 inhibitors.
Thorat DA; Doddareddy MR; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
Bioorg Med Chem Lett; 2011 Mar; 21(6):1593-7. PubMed ID: 21353544
[TBL] [Abstract][Full Text] [Related]
60. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]